Tyrosine kinase inhibitors (TKIs)
1 article · search the full text for this term
-
Cardiotoxicity Associated with Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: An Overview of Mechanisms, Clinical Implications, and Management Strategies
Abstract: Tyrosine kinase inhibitors have greatly enhanced the outlook for individuals diagnosed with Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia. However, these therapeutic agents are associated with Cardiotoxicities and can manifest as left ventricular dysfunction, which may progress to heart failure, along with electrocardiographic abnormalities, dysrhythmias, hypertension, myocardial ischemia, and thromboembolic events. The unclear frequency of drug-induced cardiovascular complications, coupled with uncertainties regarding their reversibility and long-term …
Published in Research and Reviews: Journal of Oncology and Hematology · Vol. 13, Issue 3, 2024 · pp. 18–24 Read article